JOHNSON & JOHNSON

NYSE: JNJ·New Brunswick, New Jersey·

Price
$282.55
Base IV
$140.03

Valuation snapshot

Above bull case

At $282.55, the price is above even our bull case of $194.72.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$140.03
50% of the price · range $89.87–$194.72
Price vs base case
102% above
$282.55 against $140.03
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $89.87 to bull $194.72. Values per share.

Price against each value

Bear case
$89.87
Price 214% above
No growth
…
—
Base case
$140.03
Price 102% above
Researched byClaude Opus 5.5
Valuation Nov 13, 2026 · Price as of Nov 16, 2026How we got here

What does Johnson & Johnson do?

Johnson & Johnson makes prescription medicines and medical devices that help doctors treat cancer, immune diseases, heart problems and brain disorders, and perform surgery.

It brought in $99.3B of sales in the 12 months to Sep 2026.

Led by Joaquin Duato, Chairman of the Board and Chief Executive Officer since 2022. Johnson & Johnson 2026 Proxy Statement (Form DEF 14A)

Industry
Healthcare
Based in
New Brunswick, New Jersey
Trades on
NYSE as JNJ

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 16¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 32¢ of every dollar.

  • Making what it sells32¢
  • Research and development16¢
  • Sales, marketing and admin26¢
  • Everything else, including interest8¢
  • Tax2¢
  • Left as profit16¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Johnson & Johnson, and for what?

Johnson & Johnson makes prescription medicines and medical devices. Its larger segment, Innovative Medicine, sells drugs for cancer, immune diseases, mental health and other conditions. Its MedTech segment sells heart devices, surgical tools, orthopaedic implants and contact lenses. In 2025 it had $94.2 billion of sales, about 43% of them outside the U.S.

The company sells mainly to drug wholesalers, distributors, retailers, hospitals, clinics, doctors and eye care professionals, and much of the final bill is paid by insurers and government health programs such as Medicare.

  • Innovative Medicine

    64%

    Prescription medicines for cancer (such as DARZALEX and CARVYKTI), immune diseases (TREMFYA, STELARA), brain and mental health (SPRAVATO, CAPLYTA), lung blood pressure, HIV, and heart and metabolism. DARZALEX alone was about 15% of total company sales in 2025.

  • MedTech

    36%

    Medical devices: heart products (including Abiomed heart pumps and Shockwave), orthopaedic implants (DePuy Synthes), surgical tools (Ethicon), and vision products such as ACUVUE contact lenses and TECNIS lens implants.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Wilson Biologics Manufacturing Campus — Wilson, United States. Two adjacent $2+ billion advanced-technology biologics plants that will expand production of J&J's monoclonal-antibody portfolio in oncology, immunology and neuroscience, supporting more than 70 planned filings/launches by decade's end.
  • Janssen Sciences Ireland Biopharmaceutical Campus — Ringaskiddy, Cork, Ireland. A World Economic Forum 'Global Lighthouse' biologics supply-chain hub that has received hundreds of millions of euros in repeated expansions, underpinning ex-U.S. supply of J&J's biologic medicines.
  • Janssen Beerse/Geel Campus — Beerse, Belgium. J&J's largest pharmaceutical R&D campus outside the U.S., spanning discovery-to-commercial-supply capabilities; the co-located Geel site alone produces roughly 60% of J&J's global active pharmaceutical ingredient capacity.
  • J&J Vision (Vistakon) Jacksonville Campus — Jacksonville, United States. Manufactures roughly 90% of the U.S. supply of ACUVUE contact lenses (about 1.7 billion lenses/year), with a new $1 billion+ investment expanding manufacturing, packaging and distribution capacity through 2028.
  • Raritan Cell Therapy Manufacturing Facility — Raritan, United States. The largest cell therapy manufacturing facility in the U.S., producing CARVYKTI (with partner Legend Biotech) with installed capacity for up to 10,000 patients annually, a key growth driver in J&J's oncology franchise.
See them on the globe

Johnson & Johnson Form 10-K for fiscal 2025 (Item 1 Business)

How is the business doing?

Sales grew from $82.6B in 2020 to $94.2B in 2025, about 3% a year.

After paying for its upkeep and new investment, it had $20.6B of cash to spare in the 12 months to Sep 2026.

Sales$94.2B
20172025
Free cash flow$19.7B
20172025
Each bar is one fiscal year (2017–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

The company says it exists to build a world where complex diseases are prevented, treated and cured, guided by its long-standing value statement, Our Credo.

“With Our Credo as the foundation, the Company believes health is everything.”

Johnson & Johnson Form 10-K for fiscal 2025

Who is responsible for the plan?

Roles checked November 13, 2026.

What management says it is working on now:

Reported sales, Full year 2026
$100.8 billion to $101.4 billion (7.0% to 7.6% growth)
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)
Sales growth excluding currency effects and deals, Full year 2026
6.2% to 6.8%
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)
Adjusted earnings per share, Full year 2026
$11.60 to $11.75 (7.5% to 8.9% growth)
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook (8-K Exhibit 99.1)
Orthopaedics business separation, Within 18 to 24 months of October 2025
Completed
Johnson & Johnson Form 10-K for fiscal 2025
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is slowing. In Q3 2026 it sold 6% more than a year earlier. The year before, quarters averaged 8%.

Since Sep 2026 the share price has risen 1%, from $278.43 to $282.55.

Bull $194.72Base $140.03Bear $89.87Sep 4Nov 16 · $282.55
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start September 4, 2026.

Recently

Coming up

Our own estimate moved too: the base case went from $152.60 to $140.03 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Talc lawsuits

    The company faces many lawsuits claiming that talc body powders, mainly JOHNSON'S Baby Powder, caused harm, and some cases involve thousands of plaintiffs. It does not buy outside insurance for these claims, so large payouts would come from its own funds.

    From the company's own filingsWould hit how much of each sale it keepsJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)

  2. Cheaper copies of former best-sellers

    STELARA sales fell 41.3% in 2025 as cheaper copycat versions launched, and the company expects further declines. It also expects copies of OPSUMIT in 2026 and says a copy of SIMPONI could cut its sales significantly.

    From the company's own filingsWould hit how fast sales growJohnson & Johnson Form 10-K for fiscal 2025

  3. Government drug price setting in the U.S.

    Under the Inflation Reduction Act, Medicare prices set by the government for XARELTO, STELARA and IMBRUVICA began in 2026. ERLEADA will follow in 2028. The company is challenging the law in court.

    From the company's own filingsWould hit how fast sales growJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)

  4. Patent expiries on key drugs

    Competitors increasingly challenge its patents, and sales of a drug can drop quickly once its patents expire. The core U.S. patents on DARZALEX, its biggest product, expire in 2029, and TREMFYA's main U.S. patent is expected to expire in 2031.

    From the company's own filingsWould hit how fast sales growJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)

  5. Tariffs and pricing pressure

    U.S. tariffs, and the risk of other countries retaliating, can raise costs. The company said tariffs helped push MedTech profit margins down in the second quarter of 2026. Insurers, drug-benefit managers and discount programs also keep pushing prices lower.

    From the company's own filingsWould hit how much of each sale it keepsJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)

  6. Orthopaedics separation may not go as planned

    The separation needs board, regulator and works council approvals. The company says it may not get the benefits it expects, and its share price may move more than usual around the separation.

    From the company's own filingsJohnson & Johnson Form 10-K for fiscal 2025 (Item 1A Risk Factors)

  7. MedTech grew only 2.5% in Q3 2026 and missed estimates.

    From our researchWould hit how fast sales growCNBC: J&J Q3 2026 earnings

  8. 2026 adjusted operational EPS guidance of $10.95-$11.05 is only about 2% growth on 7% sales growth, which points to margin pressure.

    From our researchWould hit how much of each sale it keepsJ&J Q3 2026 prepared remarks

Is it a good business?

From 2017 to 2025 it earned between 2% and 51% on its shareholders' equity, a median of 25%.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on equity33%
20172025
Return on invested capital is operating profit after tax (at the median effective rate, 14%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares has held roughly steady over the past year.

It owes $27.4B more than it holds in cash. An operating-profit comparison is unavailable from the published quarters.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $282.55. Our put its value between $89.87 and $194.72, with $140.03 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $89.87

This scenario assumes J&J's recent pickup to about 6% sales growth fades to low single digits as the medical-device business stays sluggish and government drug-price cuts bite, while lawsuit costs keep profits below recent levels.

Base case, $140.03

This scenario assumes J&J keeps growing sales at around 5% a year for the next few years, close to its recent pace of about 6%, before slowly settling down, with profits holding near their usual high levels.

Bull case, $194.72

This scenario assumes J&J's new medicines keep sales growing at about 6-7% a year, similar to its best recent quarters, with profits edging higher as faster-growing drugs make up more of the business.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 102%

For Johnson & Johnson to be worth today's $282.55, sales would need to grow about 20.7% a year. We assume 4.5%. Over the last 5 years, sales grew 1.7% a year.

−5%0%+5%+10%+15%+20%+25%Past 5 yrs 1.7%We assume 4.5%Price needs 20.7%

Or, if sales grow 4.5% as we assume, the price works with a profit margin of 62.2% (we assume 32.0%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 20.7% a year?

Try your own numbers

We're moderately sure of this range: it scores 63 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $140.03 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average4.5%
  • Operating margin32.0%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$140.03 -50.4%

Build